Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422994 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole
A Phase 1 study of Restless Legs Syndrome, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT00422994: Completed Phase 1 study of Restless Legs Syndrome, sponsored by GlaxoSmithKline.
NCT00422994 is a Phase 1 study of Restless Legs Syndrome that has completed, run by GlaxoSmithKline. The registered enrollment target is 48 participants, below the 93-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (48% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00422994, a Phase 1 study of Restless Legs Syndrome, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.
Conditions Studied
Interventions
- DRUG ropinirole dosing for up to 28 days
Study Locations (2)
Minnesota
- GSK Investigational Site - Minneapolis
Other
- GSK Investigational Site - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-04 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
What the finished NCT00422994 record still lists
NCT00422994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 93-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which ropinirole dosing for up to 28 days is the first listed.
NCT00422994 reports a single indexed study location in Minnesota, Other.
Frequently Asked Questions
What is clinical trial NCT00422994 about?
NCT00422994 is a clinical study titled "A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole". This study will investigate the effects of severe renal impairment and hemodialysis on the characteristics of the drug, ropinirole.
What is the current status of trial NCT00422994?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2006-04. Estimated completion is 2006-12.
What conditions does trial NCT00422994 study?
This clinical trial studies the following conditions: Restless Legs Syndrome.
What interventions are being tested in trial NCT00422994?
The interventions under investigation include: ropinirole dosing for up to 28 days (DRUG).
Who is sponsoring clinical trial NCT00422994?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00422994 being conducted?
This trial has 2 study locations across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restless Legs Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00422994's enrollment target sits among peer trials
48 8th of 14 higher than 7 of 14 other Restless Legs Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Restless Legs Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Benefits of a Cannabidiolic Acid Topical Cream for the Treatment of Restless Leg Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers
COMPLETED · Phase 1
-
Blood Changes After Exercise in Restless Legs Syndrome
RECRUITING · NA
-
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy
ACTIVE NOT RECRUITING · Phase 4
-
Response to an Investigational Device in Patients With Restless Legs Syndrome
ACTIVE NOT RECRUITING · NA
-
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia